- Previous Close
1.3300 - Open
1.3100 - Bid 1.3000 x 100
- Ask 1.3600 x 300
- Day's Range
1.2601 - 1.3300 - 52 Week Range
0.4100 - 1.9300 - Volume
1,190,414 - Avg. Volume
1,061,973 - Market Cap (intraday)
239.303M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9000 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.65
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
www.nektar.comRecent News: NKTR
View More
Performance Overview: NKTR
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKTR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKTR
View MoreValuation Measures
Market Cap
244.83M
Enterprise Value
85.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.80
Price/Book (mrq)
3.07
Enterprise Value/Revenue
0.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-190.09%
Return on Assets (ttm)
-20.16%
Return on Equity (ttm)
-128.02%
Revenue (ttm)
93.16M
Net Income Avi to Common (ttm)
-177.08M
Diluted EPS (ttm)
-0.9000
Balance Sheet and Cash Flow
Total Cash (mrq)
271.24M
Total Debt/Equity (mrq)
275.58%
Levered Free Cash Flow (ttm)
-55.72M
Research Analysis: NKTR
View MoreCompany Insights: NKTR
NKTR does not have Company Insights
Research Reports: NKTR
View MoreLowering target price to $0.58
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.584000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $0.63
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.632000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $0.93
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.928000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about NKTR?
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $1.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target